For all press and media enquiries please contact mediarelations@chiesi.com
- Transaction expands Chiesi’s rare disease medicine portfolio - All cash acquisition at US$14.50 per ADS, plus Contingent Value Rights of up to an additional US$2.50 per ADS based on certain Filsuvez® milestones being achieved - Total Transaction value of up to US$1.48 Billion with upfront…
Following the recent statements appeared in the media, Chiesi Farmaceutici would like to reiterate that the Company is not involved in the events concerning the company Holostem Terapie Avanzate s.r.l. ("Holostem"). The investments in support of Holostem have been carried out directly by Valline…
The Manifesto was signed with the CGIL, CISL, and UIL trade unions on the International Day for the Elimination of Violence Against Women. The goal is to ensure that all Group employees adopt respectful and considerate behaviour. Parma (Italy) November 28, 2022 – On the International Day for the…
The new center of excellence for the development and production of biologic drugs, currently under construction, will be built in Parma in the area of the production plant; Construction of the building is rapidly progressing, and it is scheduled to receive its first technological installations by…
The new Digital Health Solution aims at offering patients and healthcare professionals a comprehensive set of services and solutions targeted at improving outcomes for chronic respiratory diseases. Parma (Italy) and Crystal Lake (Illinois) October 18 th, 2022 – Chiesi Group, the international…
Chronic obstructive pulmonary disease, or COPD, is the third leading cause of death in the world, causing 300,000 annual deaths in Europe 1 At the European Respiratory Society Congress, Chiesi Group presents an additional option to address the needs of COPD patients: Chiesi’s extrafine triple…
The Board of Directors and the Management Team will ensure leadership continuity in this transitional phase until a new CEO is formally appointed. A new chapter opens at Chiesi as the 11-year tenure of CEO Ugo Di Francesco comes to a close at the end of 2022. The announcement that Chiesi has begun a…
Like many around the world, the people at Chiesi are shocked by the ongoing conflict as we witness the distress of all those affected. Chiesi strongly condemns all acts of violence, and we call for a peaceful and immediate resolution of the ongoing conflict in Ukraine. In more than 85 years of our…
Chiesi Group turnover of €2.42bn supported by strong international growth of 8.6% Growth across global markets; China up 22%, US up >10% Continued focus on innovation: Chiesi invests almost 20% of turnover in R&D in 2021 Chiesi recognised as Top Employer in eight global markets and as Top Employer…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
